|
| | HB5318 Enrolled | | LRB102 25274 BMS 34547 b |
|
|
1 | | AN ACT concerning regulation.
|
2 | | Be it enacted by the People of the State of Illinois,
|
3 | | represented in the General Assembly:
|
4 | | Section 5. The Illinois Insurance Code is amended by |
5 | | changing Section 356u as follows:
|
6 | | (215 ILCS 5/356u)
|
7 | | Sec. 356u. Pap tests and prostate cancer screenings |
8 | | prostate-specific antigen tests .
|
9 | | (a) A group policy of accident and health insurance that |
10 | | provides coverage
for hospital or medical treatment or |
11 | | services for illness on an
expense-incurred basis and is |
12 | | amended, delivered, issued, or renewed after January 1, 2024 |
13 | | the
effective date of this amendatory Act of 1997 shall |
14 | | provide coverage , without imposing a deductible, coinsurance, |
15 | | copayment, or any other cost-sharing requirement, for all of
|
16 | | the
following:
|
17 | | (1) An annual cervical smear or Pap smear test for |
18 | | female insureds.
|
19 | | (2) An annual prostate cancer screening digital rectal |
20 | | examination and a prostate-specific
antigen test, for male |
21 | | insureds upon the recommendation of a physician licensed
|
22 | | to practice medicine in all its branches for:
|
23 | | (A) asymptomatic men age 50 and over;
|
|
| | HB5318 Enrolled | - 2 - | LRB102 25274 BMS 34547 b |
|
|
1 | | (B) African-American men age 40 and over; and
|
2 | | (C) men age 40 and over with a family history of |
3 | | prostate cancer.
|
4 | | (3) Surveillance tests for ovarian cancer for female |
5 | | insureds who are at risk for ovarian cancer. |
6 | | (b) This Section shall not apply to agreements, contracts, |
7 | | or policies that
provide coverage for a specified disease or |
8 | | other limited benefit coverage.
|
9 | | (c) This Section does not apply to coverage of prostate |
10 | | cancer screenings to the extent such coverage would disqualify |
11 | | a high-deductible health plan from eligibility for a health |
12 | | savings account pursuant to Section 223 of the Internal |
13 | | Revenue Code. |
14 | | (d) (c) For the purposes of this Section: |
15 | | "At risk for ovarian cancer" means: |
16 | | (1) having a family history (i) with one or more |
17 | | first-degree relatives with ovarian cancer, (ii) of |
18 | | clusters of women relatives with breast cancer, or (iii) |
19 | | of nonpolyposis colorectal cancer; or |
20 | | (2) testing positive for BRCA1 or BRCA2 mutations. |
21 | | "Prostate cancer screening" means medically viable methods |
22 | | for the detection and diagnosis of prostate cancer, including |
23 | | a digital rectal exam and the prostate-specific antigen test |
24 | | and associated laboratory work. "Prostate cancer screening" |
25 | | includes medically necessary subsequent follow-up testing as |
26 | | directed by a health care provider, including, but not limited |
|
| | HB5318 Enrolled | - 3 - | LRB102 25274 BMS 34547 b |
|
|
1 | | to: |
2 | | (1) urinary analysis; |
3 | | (2) serum biomarkers; and |
4 | | (3) medical imaging, including, but not limited to, |
5 | | magnetic resonance imaging. |
6 | | "Surveillance tests for ovarian cancer" means annual |
7 | | screening using (i) CA-125 serum tumor marker testing, (ii) |
8 | | transvaginal ultrasound, (iii) pelvic examination.
|
9 | | (Source: P.A. 94-122, eff. 1-1-06.)
|